Persistent Insurance Barriers and Cost-Sharing Challenges for PrEP Despite Accessibility Initiatives
Despite regulations to improve affordability, many individuals face insurance denials and out-of-pocket costs for PrEP, highlighting persistent barriers to HIV prevention. A recent study reveals widespread coverage issues among sexual and gender minorities across the U.S.
A recent study conducted by researchers at the City University of New York highlights ongoing issues with insurance denials and out-of-pocket costs for pre-exposure prophylaxis (PrEP), a vital HIV prevention medication, despite regulations aimed at making it more affordable and accessible. The study, involving over 11,000 sexual and gender minority individuals across the United States, found that nearly one in four respondents (23.7%) had experienced an insurance denial for PrEP at some point, and more than a third (34.6%) faced cost-sharing for PrEP or related healthcare services within the past two years.
PrEP is widely regarded as an effective strategy to reduce HIV transmission and has been classified with a "grade A" rating by the U.S. Preventive Services Task Force, which mandates that most insurers cover the drug and associated care without patient cost-sharing. However, the research reveals that these protections are not fully effective in practice. Insurance denials were notably high for certain brand-name versions such as Descovy (48.2%) and Truvada (33.4%), whereas generic formulations like TDF/FTC saw significantly lower denial rates (8.5%). Many individuals with private insurance reported substantial out-of-pocket expenses, especially for laboratory testing related to PrEP management.
Anchored in the current policy landscape, the study's authors suggest that insurers may continue to deny coverage or impose costs selectively to influence prescribing patterns, although more research is needed to confirm these practices. The findings arrive amidst concerns over potential regulatory changes, including warnings from health officials about threats to the integrity of the USPSTF.
Lead researcher Alexa D'Angelo emphasizes the importance of maintaining strong protections for PrEP users, warning that ongoing insurance barriers undermine efforts to maximize access to HIV prevention. The study underscores the need for expanded coverage and increased funding to support PrEP delivery, ensuring it remains a critical tool in the fight against HIV transmission.
For further details, the full study is published in Health Affairs: [DOI: 10.1377/hlthaff.2025.00037].
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Advances in Gene Therapy: New Insights into Genome Ejection Mechanisms of AAV Vectors
New research from the University of Osaka uncovers the molecular mechanisms of genome ejection in AAV vectors, offering promising avenues for improved gene therapy vector design and safety.
The History Encased in Every Tick Bite: Understanding Their Environmental and Epidemiological Significance
Explore how human actions and environmental changes over the centuries have transformed ticks into significant vectors of disease, revealing a complex history hidden in every bite.
Dietary Modifications Can Rapidly Improve Brain Markers Associated with Memory and Inflammation
Short-term dietary changes, such as low-calorie or low-carb diets, can quickly reduce brain inflammation markers and improve cognitive health, especially in individuals with early-stage fatty liver disease. Discover how diet impacts brain metabolism in this groundbreaking study.
Rise in Childhood Contact Allergies Over Two Decades
A recent study reveals a significant rise in contact allergies among children in Finland over the last 20 years, driven by increased exposure to cosmetics and adhesives. Early cosmetic use may lead to persistent skin allergies, emphasizing the need for awareness and preventive measures.